Insecticides India Q2 FY27: consolidated PAT falls 5% YoY to ₹56 Cr as margins compress
PAT -4.97% YoY · revenue +7.62% · margins compressing
₹686.31 Cr
+7.62% YoY
₹56.17 Cr
-4.97% YoY
8.19%
-1pp YoY
₹19.3
Insecticides (India)'s consolidated (primary) Q2 FY27 print: revenue ₹686.31 Cr, up 7.62% YoY from ₹637.70 Cr, but PAT fell 4.97% YoY to ₹56.17 Cr from ₹59.11 Cr a year ago — profit declined even as the topline grew, the signature of margin compression rather than a demand problem. No exceptional or one-off items are disclosed on the face of either statement, so this is a straight reported-number read with no adjustment required. Standalone PAT of ₹50.58 Cr runs roughly 11% below the consolidated figure, with subsidiaries/the jointly controlled entity contributing the gap — a divergence worth flagging since readers may encounter either number elsewhere.
Q2 FY-2027 vs prior quarters
Sequentially the picture looks very different: revenue is up 12.23% and PAT up 28.02% versus Q1 FY27's monsoon-depressed base (revenue ₹611.52 Cr, PAT ₹43.87 Cr, NPM 7.11%, OPM 11.06%) — but per YoY-primacy this QoQ jump is a seasonal/base-effect rebound, not the headline story. Net margin compressed to ~8.20% of total income from 9.23% a year ago, and operating margin eased to roughly 13.5% from ~14.0% YoY, even as EBITDA grew in absolute ₹ Cr terms; the squeeze traces to cost of materials consumed and purchase of stock-in-trade rising faster than revenue, per the expense break-up in the filing.
The stock went into the print at ₹547.45, down 6.4% over the past month of trading.
For context: PAT has now risen for 3 consecutive quarters.
What the summary numbers don't show
Basic EPS ₹19.30 consolidated (₹17.38 standalone) vs ₹20.31 YoY and ₹15.08 QoQ
No explicit FY27 revenue or PAT guidance restated. MD deferred full-year targets pending H2 review, citing weak Q1 from monsoon. Granuvia & Spinoace targeted at ₹30–35 Cr combined gross FY27. KAEROS targeting 100% CAGR initially, then 50–60%. Capex to normalize at ₹30–40 Cr maintenance post-Sotanala.
Management offered no formal FY27 revenue or PAT guidance on the Q1 concall, deferring full-year targets pending an H2 review after a rain-hit Q1 — so there is no numeric bar to grade this print against (vsGuidance: unknown, not beat/miss). No management press release was available for this result, so there is no company quote to cross-check against the numbers this quarter. A pre-result preview (Univest, Sep 18, 2026) flagged margin trajectory and the Granuvia ramp as the quarter's swing factors but carried no numeric consensus estimate, so vsStreet is also unknown. The filing does not break out Granuvia/Spinoace or KAEROS revenue, so the ₹30–35 Cr combined FY27 target and KAEROS' CAGR goals cited on the prior concall cannot be checked this quarter. Alongside the results, the board declared an interim dividend of ₹5/share (record date Nov 12, 2026, payable from Nov 17, 2026) and approved a new Additional Independent Director and a new AVP for Tech Services Projects & Manufacturing Excellence — governance actions unrelated to the quarter's numbers.
W1
Whether OPM holds near the ~13.5% Q2 level or slips further in H2 — flagged as the key swing factor in the pre-result preview
W2
Granuvia & Spinoace combined gross revenue vs the ₹30–35 Cr FY27 target cited on the Q1 concall — no product-level split disclosed this quarter
W3
H2 capex run-rate against the ₹30–40 Cr/quarter maintenance guidance post-Sotanala — H1 consolidated capex was ₹55.76 Cr (~₹28 Cr/quarter)
Consolidated PAT (₹56.17 Cr) exceeds standalone (₹50.58 Cr) by ~11% via subsidiary/JV contribution (JV share ₹0.23 Cr); other income is negative in both statements (-₹0.88 Cr standalone, -₹0.84 Cr consolidated); no exceptional items disclosed on the face of the P&L.
Informational and educational content only. Not investment advice.